<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844284</url>
  </required_header>
  <id_info>
    <org_study_id>12-301</org_study_id>
    <nct_id>NCT01844284</nct_id>
  </id_info>
  <brief_title>AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population</brief_title>
  <acronym>ABSORB JAPAN</acronym>
  <official_title>A Clinical Evaluation of AVJ-301 (Absorb™ BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter,
      Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in
      the treatment of subjects with ischemic heart disease caused by de novo native coronary
      artery lesions in Japanese population by comparing to approved metallic drug eluting stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Absorb™ BVS is currently in development at Abbott Vascular. Not available for sale in the US
      or Japan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">January 16, 2019</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>1 month</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>6 months</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>1 year</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>2 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>3 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>4 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death/Any MI/Revascularization (DMR)</measure>
    <time_frame>5 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>1 month</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>6 months</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>1 month</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>6 months</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 month</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>1 month</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>6 months</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven TVR (ID-TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 month</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>1 month</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>1 month</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>6 months</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>1 year</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>2 years</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>3 years</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>4 years</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</measure>
    <time_frame>5 years</time_frame>
    <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel MI (TV-MI)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Acute (≤ 1 day)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Subacute (&gt;1 - 30 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Late (31 - 365 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Very Late (366 - 730 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Very Late (731 - 1095 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Very Late (1096 - 1460 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis</measure>
    <time_frame>Very Late (1461 - 1825 days)</time_frame>
    <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Loss (Non-inferiority)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Pre-Nitroglycerin (NTG)</measure>
    <time_frame>2 years</time_frame>
    <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate Vaso-reactivity Analysis/ In-device Mean Lumen Diameter: Absolute Vaso Dilatation</measure>
    <time_frame>2 years</time_frame>
    <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.
Absolute Vaso dilatation = Post Nitroglycerin (NTG) - Pre Nitroglycerin (NTG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Post-Nitroglycerin (NTG)</measure>
    <time_frame>2 years</time_frame>
    <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI, ID-TLR (MACE)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Not Ischemia-driven TLR (NID-TLR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-Target Vessel MI (NTV-MI)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Absorb™ BVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Absorb™ BVS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE PRIME®/XIENCE Xpedition™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving XIENCE PRIME®/XIENCE Xpedition™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME®/XIENCE Xpedition™</intervention_name>
    <description>Subjects receiving XIENCE PRIME®/XIENCE Xpedition™</description>
    <arm_group_label>XIENCE PRIME®/XIENCE Xpedition™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb™ BVS</intervention_name>
    <description>Subjects receiving Absorb™ BVS</description>
    <arm_group_label>Absorb™ BVS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 20 years of age.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia) suitable for elective percutaneous coronary intervention (PCI).

          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          5. Subject must be able to take dual antiplatelet therapy for up to 1 year following the
             index procedure and anticoagulants prior/during the index procedure. Therefore the
             subject has no known allergic reaction, hypersensitivity or contraindication to
             aspirin, clopidogrel, ticlopidine or heparin.

          6. Female subject of childbearing potential must not be pregnant* at the index procedure
             and does not plan pregnancy for up to 1 year following the index procedure.

             * Except for non-pregnancy is apparent, negative pregnancy result within 7 days prior
             to the index procedure is required.

          7. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for up to 1 year following the index procedure.

          8. Subject agrees to not participate in any other investigational or invasive clinical
             study for a period of 13 months following the index procedure

        Exclusion Criteria:

          1. Elective surgery is planned within 1 year after the procedure that will require
             general anesthesia or discontinuing either aspirin or Thienopyridine.

          2. Subject has known hypersensitivity or contraindication to device material and its
             degredants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
             be adequately pre-medicated.

          3. Subject has a known contrast sensitivity that cannot be adequately pre-medicated.

          4. Subject had an acute myocardial infarction (AMI) within 72 hours of the index
             procedure

               -  The subject is currently experiencing clinical symptoms consistent with new onset
                  AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes

               -  Creatine Kinase (CK) and Creatine Kinase - Muscle and Brain (CK-MB) have not
                  returned to within normal limits at the time of index procedure.

          5. Subject has an unstable cardiac arrhythmia which is likely to become hemodynamically
             unstable due to arrhythmia.

          6. Subject has a known left ventricular ejection fraction (LVEF) &lt; 30% (LVEF may be
             obtained at the time of the index procedure if the value is unknown and the
             investigator believes it is necessary).

          7. The target vessel was treated by PCI within 12 months.

          8. Prior PCI within the non-target vessel is acceptable if performed anytime &gt; 30 days
             before the index procedure or between 24 hours and 30 days before the index procedure
             if successful and uncomplicated.

          9. Subject requires future staged PCI either in target or non target vessels.

         10. Subject has a malignancy that is not in remission.

         11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus,
             etc.,). Note: corticosteroids are not included as immunosuppressant therapy, diabetes
             mellitus is not regarded as autoimmune disease.

         12. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         13. Subject has previously received or scheduled to receive radiotherapy to coronary
             artery (brachytherapy), or chest/mediastinum.

         14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin
             or any other agent for any reason).

         15. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         16. Subject has a documented or suspected cirrhosis of Child-Pugh ≥ Class B.

         17. Subject has known renal insufficiency;

               -  Dialysis at the time of screening.

               -  An estimated Glomerular filtration rate (GFR) &lt; 30 ml/min/1.73m2

         18. Subject is high risk of bleeding, or difficult to have appropriate treatment;

               -  Has a history of bleeding diathesis or coagulopathy

               -  Has had a significant gastro-intestinal or significant urinary bleed within the
                  past six months

               -  Has prior intracranial bleed

               -  Has prior intracranial bleed (including severe permanent neurologic deficit that
                  seem to be caused by previous intracranial bleeding)

               -  Has known intracranial pathology that may cause intracranial bleeding per an
                  investigator assessment (e.g. untreated aneurysm &gt; 5 mm, arteriovenous
                  malformation)

               -  Subject will refuse blood transfusions

         19. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             (TIA) within the past six months,

         20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion.

         21. Subject has life expectancy &lt; 3 year.

         22. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason.

         23. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

         24. Subject whose willingness to volunteer in a clinical investigation could be unduly
             influenced by the expectation, whether justified or not, of benefits associated with
             participation or of retaliatory response from senior members of a hierarchy in case of
             refusal to participate (e.g. subordinate hospital staff or sponsor staff) or subject
             is unable to read or write.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University</name>
      <address>
        <city>Toyoake-shi</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ShinTokyo</name>
      <address>
        <city>Matsudo-shi</city>
        <state>Chiba</state>
        <zip>270-2232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkoga Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanaoka Seishu Memorial Cardiovascular Clinic</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>062-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University</name>
      <address>
        <city>Kyoto</city>
        <state>Honshu</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansairosai Hospital</name>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba Medical Center</name>
      <address>
        <city>Tsukuba-shi</city>
        <state>Ibaraki</state>
        <zip>305-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University</name>
      <address>
        <city>Isehara-shi</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonankamakura General Hospital</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Tobu Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazak Medical Association Hospital</name>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenri Hospital</name>
      <address>
        <city>Tenri-shi</city>
        <state>Nara</state>
        <zip>632-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center Jichi Medical University</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Sekishinkai</name>
      <address>
        <city>Sayama-shi</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tokyo</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Museum</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakakibara Memorial Hospital</name>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <zip>183-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Itabashi-Ku</city>
        <state>Tokyo</state>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>106-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo University</name>
      <address>
        <city>Tochigi</city>
        <state>Utsunomiya</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Kimiidera</city>
        <state>Wakayama</state>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University</name>
      <address>
        <city>Ube-shi</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Vascular Japan Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <zip>108-6304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <results_first_submitted>July 24, 2017</results_first_submitted>
  <results_first_submitted_qc>September 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2019</results_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorb™ BVS</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>Bioreabsorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary artery restenosis</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The target sample size was approximately 400 subjects (266 in the Absorb arm and 134 in the XIENCE arm) enrolled in approximately 40 investigational sites in Japan. First subject was enrolled on April 27, 2013 and the last subject completed 5-year follow-up on January 16, 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS</description>
        </group>
        <group group_id="P2">
          <title>XIENCE PRIME/XIENCE Xpedition</title>
          <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266">Intent-to-treat (ITT) population</participants>
                <participants group_id="P2" count="134">Intent-to-treat (ITT) population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS</description>
        </group>
        <group group_id="B2">
          <title>XIENCE PRIME/XIENCE Xpedition</title>
          <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="9.4"/>
                    <measurement group_id="B2" value="67.3" spread="9.6"/>
                    <measurement group_id="B3" value="67.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death/Any MI/Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/All MI</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/All MI</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven TVR (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
        <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia-driven Revascularization (ID-TLR)</title>
          <description>A revascularization is considered ischemia-driven if associated with any of the following:
Positive functional ischemia study including positive FFR
Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA
Angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.
Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
        <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))</title>
          <description>- Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>6 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>1 year</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>2 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>3 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>4 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel MI (TV-MI)</title>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel MI (TV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Acute (≤ 1 day)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Subacute (&gt;1 - 30 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Late (31 - 365 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Very Late (366 - 730 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Very Late (731 - 1095 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Very Late (1096 - 1460 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis</title>
        <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Very Late (1461 - 1825 days)</time_frame>
        <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis</title>
          <description>ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation
Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation
Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation
Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Stent/scaffold thrombosis event rates were determined according to the the analysis population with excluding subjects who are lost to follow-up through given time point without any Stent/Scaffold Thrombosis event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Late Loss (Non-inferiority)</title>
        <time_frame>13 months</time_frame>
        <population>Full Analysis Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Late Loss (Non-inferiority)</title>
          <population>Full Analysis Set Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Pre-Nitroglycerin (NTG)</title>
        <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
        <time_frame>2 years</time_frame>
        <population>Full Analysis Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Pre-Nitroglycerin (NTG)</title>
          <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
          <population>Full Analysis Set Population</population>
          <units>millimetre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.52"/>
                    <measurement group_id="O2" value="2.76" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nitrate Vaso-reactivity Analysis/ In-device Mean Lumen Diameter: Absolute Vaso Dilatation</title>
        <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.
Absolute Vaso dilatation = Post Nitroglycerin (NTG) - Pre Nitroglycerin (NTG)</description>
        <time_frame>2 years</time_frame>
        <population>Full Analysis Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Nitrate Vaso-reactivity Analysis/ In-device Mean Lumen Diameter: Absolute Vaso Dilatation</title>
          <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.
Absolute Vaso dilatation = Post Nitroglycerin (NTG) - Pre Nitroglycerin (NTG)</description>
          <population>Full Analysis Set Population</population>
          <units>millimetre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.14"/>
                    <measurement group_id="O2" value="0.07" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Post-Nitroglycerin (NTG)</title>
        <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
        <time_frame>2 years</time_frame>
        <population>Full Analysis Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Post-Nitroglycerin (NTG)</title>
          <description>Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.</description>
          <population>Full Analysis Set Population</population>
          <units>millimetre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.54"/>
                    <measurement group_id="O2" value="2.82" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI, ID-TLR (MACE)</title>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI, ID-TLR (MACE)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Not Ischemia-driven TLR (NID-TLR)</title>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Not Ischemia-driven TLR (NID-TLR)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-Target Vessel MI (NTV-MI)</title>
        <time_frame>5 years</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME/XIENCE Xpedition</title>
            <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-Target Vessel MI (NTV-MI)</title>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS</description>
        </group>
        <group group_id="E2">
          <title>XIENCE PRIME/XIENCE Xpedition</title>
          <description>Subjects receiving XIENCE PRIME/XIENCE Xpedition</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POSTINFARCTION ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ANGLE CLOSURE GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORNEAL DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DISUSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM T WAVE PEAKED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL LIGAMENT OSSIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THALAMUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>AORTIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>REPERFUSION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POSTINFARCTION ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>PITUITARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>STEROID WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AGE-RELATED MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANGLE CLOSURE GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORNEAL DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CHEILITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRITIS ATROPHIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PAROTID GLAND ENLARGEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DISUSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTOID REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PYODERMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TINEA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OPEN WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM T WAVE PEAKED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>METABOLIC ALKALOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SERONEGATIVE ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL LIGAMENT OSSIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ADRENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CHOLINERGIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>THALAMUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HEAD BANGING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NEUROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CYSTITIS NONINFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>URATE NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMATOSPERMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>NASAL MUCOSAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PAINFUL RESPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ALKALOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DIABETIC BULLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ECZEMA ASTEATOTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ECZEMA NUMMULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE SUBCUTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERKERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PARAPSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRURIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SENILE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SOLAR DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>TOOTH EXTRACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>AORTIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EXTRAVASATION BLOOD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>PERIPHERAL COLDNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>REPERFUSION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VARICOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hajime Kusano</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1626 ext +1</phone>
      <email>hajime.kusano@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

